Relieves inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses. Sold as Locoid, Locoid Lipocream. Every FDA application for this active ingredient: 8 branded and 7 generic.
As of Nov 16, 2026, FDA lists 15 applications for Hydrocortisone Butyrate (sold as Locoid, Locoid Lipocream), first approved Mar 31, 1982, with 1 new use approved and 0 published complete response letters.
| Product | Part | Spending, 2025 | Change | Beneficiaries |
|---|---|---|---|---|
| Hydrocortisone Butyrate | Part D | $2.5M | -56% | 5,619 |
| Study | Phase | Status | Posted |
|---|---|---|---|
| Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)Coronavirus Infection (COVID-19), Pulmonary Arterial Hypertension · Duke University | — | Recruiting | Feb 20, 2020 |
| Mar 31, 1982 | LocoidNDA 18514 · New active ingredient | Bausch | 10 | Marketed |
| Oct 29, 1982 | LocoidNDA 18652 · New dosage form | Precision Dermat | 6 | Discontinued |
| Feb 25, 1987 | LocoidNDA 19116 · New dosage form | Bausch | 5 | Marketed |
| Sep 8, 1997 | Locoid LipocreamNDA 20769 · New dosage form | Precision Dermat | 7 | Marketed |
| Jan 14, 2004 | Hydrocortisone ButyrateANDA 76364 | Taro Pharm Inds | 0 | Marketed |
| Dec 27, 2004 | Hydrocortisone ButyrateANDA 76842 | Taro | 0 | Marketed |
| Aug 3, 2005 | Hydrocortisone ButyrateANDA 76654 | Taro Pharm Inds | 0 | Marketed |
| May 18, 2007 | LocoidNDA 22076 · New dosage form | Bausch | 3 | Discontinued |
| Sep 27, 2013 | Hydrocortisone ButyrateANDA 202145 | Glenmark Pharms Ltd | 1 | Discontinued |
| Nov 21, 2017 | Hydrocortisone ButyrateANDA 209556 | The J Molner | 1 | Marketed |
| Dec 8, 2017 | Hydrocortisone ButyrateANDA 205134 | Actavis Mid Atlantic | 0 | Marketed |
| Aug 17, 2018 | Hydrocortisone ButyrateANDA 210209 | Lupin | 0 | Marketed |
| — | LocoidNDA 18795 | Yamanouchi | 0 | Discontinued |
| — | LocoidNDA 19106 | Yamanouchi | 0 | Discontinued |
| — | LocoidNDA 19819 | Yamanouchi | 0 | Discontinued |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA